Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies.

Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies.
复制标题

121 例肝移植受者巨细胞病毒和其他疱疹病毒感染:通过捐赠器官传播以及 OKT3 抗体的作用。

DOI:
10.1093/infdis/158.1.124
复制
发表时间:
1988
期刊:
The Journal of infectious diseases
影响因子:
--
通讯作者:
Ho,M
Ho,M
中科院分区:
--
文献类型:
--
作者:
Singh,N;Dummer,JS;Kusne,S;Breinig,MK;Armstrong,JA;Makowka,L;Starzl,TE;Ho,M

文献摘要

被引文献

相似文献

研究了121例成人肝移植受者移植后疱疹病毒感染的发病率、危险因素和发病率。巨细胞病毒(CMV)的总感染率为59%,单纯疱疹病毒(HSV)为35%,EB病毒(EBV)为25%,水痘带状疱疹病毒(VZV)为7%。在易感受者中,46%发生CMV原发感染,67%发生CMV再激活感染。当患者发生原发性感染时,症状性和播散性CMV疾病更常见(P<0.01,两种比较)。供体器官似乎是血清阴性受者CMV感染的唯一重要来源。OKT 3抗体的使用与原发感染患者的播散性CMV疾病相关(P= 0.04),但与再激活感染无关(P> 0.10)。虽然大多数HSV感染是口腔或生殖器再激活,但发生了3例HSV肝炎,其中1例为原发感染。在接受OKTJ的HSV血清阳性接受者中观察到53%的HSV症状再激活,而未接受OKT3的血清阳性接受者中为31%(P= 0.05)。
One hundred twenty-one adult liver transplant recipients were studied for the incidence, risk factors, and morbidity associated with herpes viruses infections after transplantation. The overall incidence of infection was 59% for cytomegalovirus (CMV), 35% for herpes simplex virus (HSV), 25% for Epstein-Barr virus (EBV), and 7% for varicella-zoster virus (VZV). Primary CMV infection occurred in 46% and reactivation CMV infection in 67% of the susceptible recipients. Symptomatic and disseminated CMV diseases were more common when patients developed primary infection (P< .01, for both comparisons). The donor organ appeared to be the only important source of CMV infection in seronegative recipients. The use of OKT3 antibodies was associated with disseminated CMV disease in patients with primary infection (P= .04)but not with reactivation infection (P> .10). Although most HSV infections were oral or genital reactivations, three cases of HSV hepatitis occurred-one was a primary infection. Symptomatic reactivations of HSV were observed in 53% of HSV-seropositive recipients who received OKTJ, versus 31% of seropositive recipients who did not receive OKT3 (P= .05).